{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:03:26Z","timestamp":1791237806002,"version":"4.1.0"},"reference-count":104,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Despite the advances of CAR-T cells in certain hematological malignancies, mostly from B-cell derivations such as non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, a significant portion of other hematological and non-hematological pathologies can benefit from this innovative treatment, as the results of clinical studies are demonstrating. The clinical application of CAR-T in the setting of acute T-lymphoid leukemia, acute myeloid leukemia, solid tumors, autoimmune diseases and infections has encountered limitations that are different from those of hematological B-cell diseases. To overcome these restrictions, strategies based on different molecular engineering platforms have been devised and will be illustrated below. The aim of this manuscript is to provide an overview of the CAR-T application in pathologies other than those currently treated, highlighting both the limits and results obtained with these settings.<\/jats:p>","DOI":"10.3390\/cells14010041","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:10:17Z","timestamp":1735888217000},"page":"41","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CAR-T Therapy Beyond B-Cell Hematological Malignancies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4703-6280","authenticated-orcid":false,"given":"Martina","family":"Canichella","sequence":"first","affiliation":[{"name":"Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"de Fabritiis","sequence":"additional","affiliation":[{"name":"Hematology, St. Eugenio Hospital, ASL Roma2, 00144 Rome, Italy"},{"name":"Department of Biomedicina e Prevenzione, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12126","article-title":"CAR T cells: Driving the road from the laboratory to the clinic","volume":"257","author":"Cheadle","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (Car) T cell therapy for malignant cancers: Summary and perspective","volume":"2","author":"Smith","year":"2016","journal-title":"J. Cell. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100838","DOI":"10.1016\/j.tranon.2020.100838","article-title":"Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of Cd33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"Pi3k orchestration of the in vivo persistence of chimeric antigen receptor modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"11","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2017.241","article-title":"CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype","volume":"29","author":"Li","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e003149","DOI":"10.1136\/jitc-2021-003149","article-title":"Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design","volume":"9","author":"Qin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","article-title":"Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells","volume":"7","author":"Qin","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of humanacute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kittel-Boselli, E., Soto, K.E.G., Loureiro, L.R., Hoffmann, A., Bergmann, R., Arndt, C., Koristka, S., Mitwasi, N., Kegler, A., and Bartsch, T. (2021). Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy. Cancers, 13.","DOI":"10.3390\/cancers13194785"},{"key":"ref_19","first-page":"2659","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"7","author":"Kelder","year":"2007","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"9","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.bbmt.2018.12.470","article-title":"Optimizing c-type lectin-like molecule 1 (Cll-1) directed car T cell therapy of acute myeloid leukemia","volume":"25","author":"Atilla","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed\/refractory acute myeloid leukemia","volume":"3","author":"Lin","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pedersen, M.G., M\u00f8ller, B.K., and Bak, R.O. (2022). Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies forTreatment of AML. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102441"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Nitika Wei, J., and Hui, A.M. (2022). Role of Biomarkers in FLT3 AML. Cancers, 14.","DOI":"10.3390\/cancers14051164"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41571-021-00556-3","article-title":"Anti-CD7 CAR T cells for T-ALL: Impressive early-stage efficacy","volume":"18","author":"Teachey","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1200\/JCO.2024.42.16_suppl.6515","article-title":"Safety and efficacy of CD7-CAR-T cell in patients with relapsed\/refractory T-lymphoblastic leukemia\/lymphoma: Phase I dose-escalation\/dose-expansion study","volume":"42","author":"Hu","year":"2024","journal-title":"JCO"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","article-title":"Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch","volume":"15","author":"Ma","year":"2019","journal-title":"Stem. Cell Rev. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e005333","DOI":"10.1136\/jitc-2022-005333","article-title":"Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers","volume":"10","author":"Tirado","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13045-021-01178-z","article-title":"CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modifcation with CXCR2","volume":"13","author":"Kershaw","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafcking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J. Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-12-3913","article-title":"Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice","volume":"73","author":"Chinnasamy","year":"2013","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eabg3072","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/07388551.2021.1988509","article-title":"Addressing the obstacles of CAR T cell migration in solid tumors: Wishing a heavy trafc","volume":"42","author":"Rahbarizadeh","year":"2022","journal-title":"Crit. Rev. Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T Cells Releasing IL-18 Convert to T-Bet(high) FoxO1(low) Efectors that Exhibit Augmented Activity against Advanced Solid Tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1038\/s41467-021-26352-2","article-title":"Regulatory T cells promote cancer immune-escape through integrin alphavbeta8-mediated TGF-beta activation","volume":"12","author":"Laine","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e133977","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-beta inhibition via CRISPR promotes the long-term efcacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1016\/j.cell.2021.11.015","article-title":"Killer fatigue: Transition to NK-cell-like phenotype is a signature of CAR-T cell exhaustion","volume":"184","author":"Hong","year":"2021","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"He, C., Zhou, Y., Li, Z., Farooq, M.A., Ajmal, I., Zhang, H., Zhang, L., Tao, L., Yao, J., and Du, B. (2020). Co-expression of IL-7 improves NKG2D-Based CAR T cell therapy on prostate Cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion. Cancers, 12.","DOI":"10.3390\/cancers12071969"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Epperly, R., Gottschalk, S., and Velasquez, M.P. (2020). A bump in the Road: How the hostile AML Microenvironment affects CAR T cell therapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00262"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cheng, K., Feng, X., Chai, Z., Wang, Z., Liu, Z., Yan, Z., Wang, Y., and Zhang, S. (2023). 4-1BB-Based CAR T cells effectively reverse exhaustion and enhance the Anti-tumor Immune Response through Autocrine PD-L1 scFv antibody. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044197"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB Signalling Network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-Targeted Therapies\u2014A Role beyond Breast Cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Uribe, M.L., Marrocco, I., and Yarden, Y. (2021). EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13.","DOI":"10.3390\/cancers13112748"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100728","DOI":"10.1016\/j.omto.2023.100728","article-title":"Ligand-Based, PiggyBac-Engineered CAR-T Cells Targeting EGFR Are Safe and Effective against Non-Small Cell Lung Cancers","volume":"31","author":"Chinsuwan","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","article-title":"Carcinoembryonic Antigen (CEA) as Tumor Marker in Lung Cancer","volume":"76","author":"Grunnet","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"123146","DOI":"10.1016\/j.talanta.2021.123146","article-title":"Dual-template rectangular nanotube molecularly imprinted polypyrrole for label-free impedimetric sensing of AFP and CEA as lung cancer biomarkers","volume":"239","author":"Taheri","year":"2022","journal-title":"Talanta"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Correa, T.S., Bocca, A.L., Figueiredo, F., Lima, E.C., Santos, M.d.F.M.A., Lacava, Z.G.M., and Campos-Da-Paz, M. (2021). Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer. Biomed. Mater., 16.","DOI":"10.1088\/1748-605X\/abe359"},{"key":"ref_59","first-page":"5681","article-title":"Use of immunotherapy in the treatment of gastric cancer","volume":"18","author":"Yang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1251539","DOI":"10.1080\/2162402X.2016.1251539","article-title":"CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside","volume":"5","author":"Zhang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1899469","DOI":"10.1080\/2162402X.2021.1899469","article-title":"Tumor Regression and Immunity in Combination Therapy with Anti-CEA Chimeric Antigen Receptor T Cells and Anti-CEA-IL2 Immunocytokine","volume":"10","author":"Cha","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of Mesothelin Immunostaining in Tumor Diagnosis","volume":"27","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular Basis and Therapeutic Implications of CD40\/CD40L Immune Checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Zhai, X., Mao, L., Wu, M., Liu, J., and Yu, S. (2023). Challenges of Anti-Mesothelin CAR-T-Cell Therapy. Cancers, 15.","DOI":"10.3390\/cancers15051357"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood.2021014760","article-title":"ROR1: An Orphan Becomes Apparent","volume":"140","author":"Kipps","year":"2022","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Rebagay, G., Yan, S., Liu, C., and Cheung, N.K. (2012). ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy. Front. Oncol., 2.","DOI":"10.3389\/fonc.2012.00034"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Groux-Degroote, S., and Delannoy, P. (2021). Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116145"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Cavdarli, S., Groux-Degroote, S., and Delannoy, P. (2019). Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors. Biomolecules, 9.","DOI":"10.3390\/biom9080311"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27213","DOI":"10.1074\/jbc.M109.087791","article-title":"Ganglioside GD3 Enhances Adhesion Signals and Augments Malignant Properties of Melanoma Cells by Recruiting Integrins to Glycolipid-Enriched Microdomains","volume":"285","author":"Ohkawa","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/pbc.26097","article-title":"Oncotargets GD2 and GD3 Are Highly Expressed in Sarcomas of Children, Adolescents, and Young Adults","volume":"63","author":"Dobrenkov","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10719-015-9606-6","article-title":"Exploring the Role and Diversity of Mucins in Health and Disease with Special Insight into Non-Communicable Diseases","volume":"32","author":"Behera","year":"2015","journal-title":"Glycoconj. J."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chen, W., Zhang, Z., Zhang, S., Zhu, P., Ko, J.K.S., and Yung, K.K.L. (2021). MUC1: Structure, Function, and Clinic Application in Epithelial Cancers. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126567"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Beatson, R., Maurstad, G., Picco, G., Arulappu, A., Coleman, J., Wandell, H.H., Clausen, H., Mandel, U., Taylor-Papadimitriou, J., and Sletmoen, M. (2015). The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and Sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125994"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Nagarajan, A., Malvi, P., and Wajapeyee, N. (2018). Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00483"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast Growth Factor Signalling: From Development to Cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.trecan.2018.09.004","article-title":"Glypicans as Cancer Therapeutic Targets","volume":"4","author":"Li","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e49392","DOI":"10.7554\/eLife.49392","article-title":"GPC1 Specific CAR-T Cells Eradicate Established Solid Tumor without Adverse Effects and Synergize with Anti-PD-1 Ab","volume":"9","author":"Kato","year":"2020","journal-title":"eLife"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41586-019-1311-3","article-title":"Distinct Modes of Mitochondrial Metabolism Uncouple T Cell Differentiation and Function","volume":"571","author":"Bailis","year":"2019","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e26618","DOI":"10.4161\/onci.26618","article-title":"Preventing surgery-induced NK cell dysfunction and cancer metastases with infuenza vaccination","volume":"2","author":"Tai","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","article-title":"Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy","volume":"27","author":"Wu","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Lu, H., Zhao, X., Li, Z., Hu, Y., and Wang, H. (2021). From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.720501"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Valeri, A., Garc\u00eda-Ortiz, A., Castellano, E., C\u00f3rdoba, L., Maroto-Mart\u00edn, E., Encinas, J., Leivas, A., R\u00edo, P., and Mart\u00ednez-L\u00f3pez, J. (2022). Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.953849"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Goldenson, B.H., Hor, P., and Kaufman, D.S. (2022). iPSC-Derived Natural Killer Cell Therapies\u2014Expansion and Targeting. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.841107"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41568-020-0259-9","article-title":"Macrophages get a CAR","volume":"20","author":"Villanueva","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zou, Z., Lin, H., Li, M., and Lin, B. (2023). Tumor\u2212associated macrophage polarization in the inflammatory tumor microenvironment. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1103149"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Boutilier, A.J., and Elsawa, S.F. (2021). Macrophage Polarization States in the Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136995"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hasan, M.N., Capuk, O., Patel, S.M., and Sun, D. (2022). The Role of Metabolic Plasticity of Tumor-Associated Macrophages in Shaping the Tumor Microenvironment Immunity. Cancers, 14.","DOI":"10.3390\/cancers14143331"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","article-title":"Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: More than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e000736","DOI":"10.1136\/jitc-2020-000736","article-title":"CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation","volume":"8","author":"Dragon","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1128\/JVI.02117-09","article-title":"T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor","volume":"84","author":"Full","year":"2010","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jiaa171","article-title":"Chimeric antigen receptors targeting human cytomegalovirus","volume":"222","author":"Ali","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.gastro.2007.11.002","article-title":"T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes","volume":"134","author":"Bohne","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ymthe.2019.02.001","article-title":"Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model","volume":"27","author":"Festag","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"103295","DOI":"10.1016\/j.isci.2021.103295","article-title":"Effective chimeric antigen receptor T cells against SARS-CoV-2","volume":"24","author":"Guo","year":"2021","journal-title":"iScience"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf \u2019 allogeneic CAR T cells: Development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up","volume":"390","author":"Taubmann","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/1\/41\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:22:09Z","timestamp":1759918929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/1\/41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cells14010041"],"URL":"https:\/\/doi.org\/10.3390\/cells14010041","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]}}}